Author Interviews, Cancer Research, HPV, Urology / 13.05.2019
HPV6 Serology Associated with Bladder Cancer
MedicalResearch.com Interview with:
[caption id="attachment_49147" align="alignleft" width="200"]
Dr. Reinstatler[/caption]
Lael S. Reinstatler, MD, MPH.
PGY 4 Urology Residency
Dartmouth Hitchcock
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Human Papillomavirus is an oncogenic virus associated with other genitourinary cancers including penile cancer.
HPV is detectable in urine and in urethral swabs and it interacts with stratified squamous epithelium which lines the majority of the genitourinary tract. Prior research has identified HPV in bladder tumors but detection methods are inconsistent.
In this study, we looked for an association with HPV serology (indicating prior HPV systemic exposure) and bladder cancer.
Dr. Reinstatler[/caption]
Lael S. Reinstatler, MD, MPH.
PGY 4 Urology Residency
Dartmouth Hitchcock
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Human Papillomavirus is an oncogenic virus associated with other genitourinary cancers including penile cancer.
HPV is detectable in urine and in urethral swabs and it interacts with stratified squamous epithelium which lines the majority of the genitourinary tract. Prior research has identified HPV in bladder tumors but detection methods are inconsistent.
In this study, we looked for an association with HPV serology (indicating prior HPV systemic exposure) and bladder cancer.
Dr. Rhee[/caption]
Chanu Rhee, MD,MPH
Assistant Professor of Population Medicine
Harvard Medical School / Harvard Pilgrim Health Care Institute
Assistant Hospital Epidemiologist
Brigham and Women’s Hospital
MedicalResearch.com: What is the background for this study?
Response: Sepsis is the body’s reaction to a serious infection that results a cascade of inflammation in the body and organ dysfunction, such as low blood pressure, confusion, or failure of the lungs, kidneys, or liver. Sepsis is a major cause of death, disability, and cost in the U.S. and around the world. Growing recognition of this problem has led to numerous sepsis performance improvement initiatives in hospitals around the country. Some of these efforts have also been catalyzed by high-profile tragic cases of missed sepsis leading to death, which may have contributed to a perception that most sepsis deaths are preventable if doctors and hospitals were only better at recognizing it.
However, the extent to which sepsis-related deaths might be preventable with better hospital-based care is unknown. In my own experience as a critical care physician, a lot of sepsis patients we treat are extremely sick and even when they receive timely and optimal medical care, many do not survive. This led myself and my colleagues to conduct this study to better understand what types of patients are dying from sepsis and how preventable these deaths might be. 
Dr. Kitchener[/caption]
Professor Henry Kitchener, MD FRCOG FRCS
University of Manchester, Manchester, UK
MedicalResearch.com: What is the background for this study?
Response: We now have reliable and affordable technologies to detect human papillomavirus (HPV), a virus which is universally accepted as the cause of cervical cancer. Various large trials confirmed that cervical screening could be improved by replacing the smear (cytology) test that has been in use for decades, with HPV testing. Many countries are now making the switch. In England, this is planned for the end of 2019. To test how to run HPV testing within the English National Health Service, a pilot was initiated in 2013 in six screening laboratories. We also wanted to determine whether the encouraging findings from the trials could be translated to everyday practice. This is important not only because we will be using different HPV tests, but also because women undergoing screening in trials are much more selected than those who are invited to population-based screening. 
